Transactions

T

Since our inception in August 2016 we have advised corporate clients, raising more than SEK 6 billion from global specialist investors, blue chip pension funds and renown mutual funds. Before taking on a fund-raising advisory assignment we perform extensive due diligence to make sure that the companies we work with are of such high quality that we can leverage our global network of highly sophisticated investors. We take pride in executing transactions for high-quality companies within the life science industry in order to help to allocate capital to promising new life-saving efforts, which has a positive impact for society as a whole.

Qlife
SEK 90m directed share issue
April 2021
Press release

Vicore Pharma
SEK 336m, directed share issue
February 2021
Press release

IRLAB Therapeutics
SEK 130m, directed share issue
December 2020
Press release

Episurf Medical
SEK 66m, directed share issue
November 2020
Press release

Xspray Pharma
SSEK 265m, directed share issue
October 2020
Press release

Hansa Biopharma
SEK 1112m, directed share issue
July 2020
Press release

Vicore Pharma
SEK 185m, directed share issue
July 2020
Press release

Cantargia
SEK 410m, directed share issue
February 2020
Press release

Episurf Medical
SEK 140m, directed share issue and rights issue
February 2020
Press release

IRLAB Theraeputics
SEK 215m, directed share issue and rights issue
December 2019
Press release

Xspray
SEK 122m, directed share issue
December 2019
Press release

Vicore Pharma
SEK 125 M, directed share issue
November 2019
Press release

Asarina Pharma
SEK 48 M, directed share issue
October 2019
Press release

Calliditas Therapeutics
SEK 300 M directed share issue and secondary sale
July 2019
Press release

Xspray
SEK 92 M, directed share issue
December 2018
Press release

Vicore Pharma
SEK 160 M directed share issue
November 2018
Press release

Hansa Biopharma
SEK 675 M directed share issue and secondary sale
November 2018
Press release

Asarina Pharma
SEK 150 M, IPO
September 2018
Press release

Vicore Pharma
NA, M&A
June 2018
Press release

Integrative Research Laboratories
SEK 139 M, directed share issue
May 2018
Press release

Xspray
SEK 88 M, directed share issue
January 2018
Press release

Hansa Biopharma
SEK 545 M, directed share issue
November 2017
Press release

Infant Bacterial Therapeutics
SEK 545 M, directed share issue and rights issue
November 2017
Press release

Xspray
SEK 132 M, IPO
August 2017
Press release

Vicore Pharma
SEK 56 M, directed share issue
February 2017
Press release

Hansa Biopharma
SEK 185 M, directed share issue
November 2016
Press release
By wiberg